Join

Compare · DXCM vs NEPH

DXCM vs NEPH

Side-by-side comparison of DexCom Inc. (DXCM) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $29.57B, about 803.3x NEPH ($36.8M).
  • Over the past year, DXCM is down 10.6% and NEPH is down 0.9% - NEPH leads by 9.7 points.
  • DXCM has hit the wire 26 times in the past 4 weeks while NEPH has been quiet.
  • DXCM has more recent analyst coverage (25 ratings vs 0 for NEPH).
PerformanceDXCM-10.56%NEPH-0.87%
2025-06-09+0.00%2026-06-08
MetricDXCMNEPH
Company
DexCom Inc.
Nephros Inc.
Price
$76.59+5.15%
$3.42-0.29%
Market cap
$29.57B
$36.8M
1M return
+25.71%
+9.44%
1Y return
-10.56%
-0.87%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
News (4w)
26
0
Recent ratings
25
0
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

NEPH

Nephros Inc.

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Latest DXCM

Latest NEPH